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Abstract
Schistosomiasis, one of the 17 neglected tropical diseases listed by the World Health Organization, presents a
substantial public health and economic burden. Of the 261 million people requiring preventive chemotherapy for
schistosomiasis in 2013, 92% of them lived in sub-Saharan Africa and only 12.7% received preventive chemotherapy.
Moreover, in 2010, the WHO reported that schistosomiasis mortality could be as high as 280 000 per year in Africa
alone.
In May 2012 delegates to the sixty-fifth World Health Assembly adopted resolution WHA65.21 that called for the
elimination of schistosomiasis, and foresees the regular treatment of at least 75% of school age children in at-risk
areas. The resolution urged member states to intensify schistosomiasis control programmes and to initiate
elimination campaigns where possible.
Despite this, in June 2015, schistosomiasis was indicated to have the lowest level of preventive chemotherapy
implementation in the spectrum of neglected tropical diseases. It was also highlighted as the disease most lacking
in progress. This is perhaps unsurprising, given that it was also the only NTD with access to drug donations but
without a coalition of stakeholders that collaborates to boost commitment and implementation.
As a consequence, and to ensure that the WHO NTDs Roadmap Targets of 2012 and World Health Assembly
Resolution WHA65.21 are met, the Global Schistosomiasis Alliance (GSA) has been set up. Diverse and representative,
the GSA aims to be a partnership of endemic countries, academic and research institutions, international development
agencies and foundations, international organizations, non-governmental development organizations, private sector
companies and advocacy and resource mobilisation partners. Ultimately, the GSA calls for a partnership to work for the
benefit of endemic countries by addressing health inequity and rural poverty.
Keywords: Neglected tropical diseases, Schistosomiasis, Global Schistosomiasis Alliance, Elimination
Multilingual abstracts
Please see Additional file 1 for translations of the abstract
into the five official languages of the United Nations.
Introduction
Schistosomiasis is one of 17 diseases that are listed by
the World Health Organization (WHO) as the group
of neglected tropical diseases (NTDs). Of these, schis-
tosomiasis presents a substantial public health and
economic burden. In 2010, the WHO reported that
schistosomiasis mortality could be as high as 280 000
per year in Africa alone [1]. Schistosomiasis is also
considered a disease of poverty [2]. For example, in
southwestern Nigeria the prevalence of Schistosoma
haematobium infection increases from 1.5% for house-
holds with an income greater than US $1 600, to 70%
for households with an income of less than US $600
[3]. Specifically, incidence of infection is concentrated
in particularly poor communities with a dependence
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on surface water, water that is often contaminated
with urine and faeces of infected individuals, and colo-
nised by snails that act as the intermediate hosts for
the schistosome [4]. Individuals, especially children,
become infected and re-infected by regular exposure
to the contaminated water [5]. Due to this relationship
with poverty and water, the distribution of schistosom-
iasis in Africa remains highly widespread and yet
highly focal at the local level [6].
Praziquantel (PZQ) is the drug of choice for effective
treatment of schistosomiasis [7]. Developed in the 1970s
by Merck and Bayer AG in Germany [8], it generated
hope for a fast reduction in morbidity in sub-Saharan
Africa where morbidity control had not developed as in
other endemic countries. The drug is easy to administer
by the aid of a dose pole for height [2], presenting ex-
tremely good efficacy in a single dose, and can be safely
administered during pregnancy and lactation [9]. Treat-
ing infected individuals could thus be straightforward.
However, despite the drug’s relatively low price, its
limited availability has long hindered progress towards
control, particularly in sub-Saharan Africa. Subsequently,
at the population-level many communities in endemic
areas still lack sufficient access to treatment. Of the
261 million people requiring preventive chemother-
apy for schistosomiasis in 2013, 92% of them lived
in sub-Saharan Africa and globally only 12.7% re-
ceived treatment by means of preventive chemother-
apy (PC), despite on-going PC campaigns [10].
There has been progress since, with 20.7% of those
requiring treatment receiving it in 2014 (equivalent to
61.6 million people) and a further increase to 28%
(equivalent to 65.2 million people of which 52.7
million represent children) in 2015 [11]. Furthermore,
in some former endemic countries in Asia, Latin
America and the Middle East, the disease has been
controlled or even eliminated, demonstrating the
feasibility of fighting schistosomiasis. In China for
example, Chairman Mao Zedong made schistosomiasis
a public health priority in the 1950s as its control was
seen to be a critical element for rural development
[12–16]. Brazil was also able to achieve significant re-
ductions in morbidity [16].
In many cases, however, a lack of both political will
and committed resources remains. For example, only a
few countries in Africa, despite recent increases in
GDP [17] have committed national resources to fight-
ing schistosomiasis and “scale-up remains slow in the
highest burden countries where 70% of the burden
occurs” [12]. Consequently, in many parts of Africa, the
expansion of control programmes is progressing too
slowly and schistosomiasis continues to be transmitted
in many rural areas, hindering economic and human
development [18]. Importantly, this seems to be the
case despite a growing interest in fighting neglected
tropical diseases in general and schistosomiasis in
particular.
With the understanding of the cost-effectiveness of
PC interventions to control or, if associated with other
interventions, support the elimination of schistosomia-
sis and other NTDs came the commitments of major
pharmaceutical manufacturers to provide the necessary
medicines free of charge. In 2012 a number of large
pharmaceutical manufacturers have pledged to con-
tinue or extend large medicinal donations under the
London Declaration on NTDs. The cumulative value of
these donations of US $17.8 bn from 2014–2020, repre-
sents the greatest growing public health donation and
additionally targets the most vulnerable afflicted popu-
lations in the world [12]. One of these donations comes
from the science and technology company Merck that
has made a commitment to donate PZQ until schistosom-
iasis has been eliminated. As a signatory of the London
Declaration on NTDs Merck has committed to a ten-fold
increase in its annual donation of PZQ (a step-wise in-
crease from 25 million to up to 250 million tablets equiva-
lent to 100 million doses a year) with a focus on African
school-age children [13].
Yet, in addition to improved supply of the drug, there
is a need for research and development into, amongst
others, combination therapies [14], and biomarkers
monitoring the emergence of drug resistance, as well as
implementation and distribution strategies and the revi-
talisation of previously used anthelmintics [15]. This is
particularly important as PZQ currently remains the
only asset in the chemotherapy armamentarium against
schistosomiasis. Furthermore, since schistosomiasis is
known to rapidly proliferate in badly planned irrigation
systems or dam structures [19], reducing infection and
transmission of the disease by means additional to ac-
cess to free regular anthelminthic treatment such as
snail control and properly organized water and sanita-
tion plans, is critical for equitable agricultural develop-
ment schemes.
Considering this potential for real impact thanks to
the growing interest in and commitments to schistosom-
iasis and at the same time the many unmet needs and
open questions, the purpose of this review is to highlight
the need of having an alliance that addresses the global
elimination of schistosomiasis by aligning these two
sides of the coin.
The need for an alliance
In May 2012 delegates to the sixty-fifth World Health
Assembly adopted resolution WHA65.21 that called for
the elimination of schistosomiasis [20]. Previous resolu-
tions and the WHO NTD Road Map of 2012 had fore-
seen the regular treatment of at least 75% of school age
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children in at-risk areas as the basis for morbidity and
disease control [21–23]. The elimination of schistosom-
iasis resolution of 2012 urged member states to intensify
schistosomiasis control programmes and to initiate elim-
ination campaigns where possible, through strengthened
health systems, preventive chemotherapy, and provision
of water and sanitation as well as hygiene, education and
snail control.
A central problem for the achievement of the above
resolution, however, is the fact that, until now, the schisto-
somiasis community has been built mainly around separ-
ate research-driven activities. These include, but are not
limited to, the EU funded CONTRAST programme,
the Bill & Melinda Gates Foundation funded Schisto-
somiasis Consortium for Operational Research and
Evaluation (SCORE) programme as well as The Schis-
tosomiasis Control Initiative (SCI), based at Imperial
College London, which has been the major body deal-
ing with implementation in Africa. Most recently, the
Research and Evidence Division of DFID has invested
in COUNTDOWN, a multidisciplinary implementa-
tion research consortium engaged in identifying best
ways to foster scale-up of preventive chemotherapy
approaches in sub-Saharan Africa.
While each organisation and its efforts are very valu-
able, coordination and communication amongst the
stakeholders involved has so far been limited. Accord-
ing to the authors, this lack of a coordinated approach
to the control and elimination of schistosomiasis as a
public health problem was reflected in the poor per-
formance of the disease vis-a-vis other NTDs in the
scorecard of the 3rd annual progress report published
by Uniting to Combat NTDs. [24]. Schistosomiasis lagged
behind, for example, onchocerciasis, soil-transmitted
helminthiasis and trachoma, which have been benefit-
ing from a partnership of organisations.
The experience of previous NTD alliances shows that
they provide a necessary platform for keeping a com-
mitted community together, whilst being able to high-
light operational research needs and freely advocate for
stronger political commitment. A significant change in
the organisation of efforts is hence considered neces-
sary to ensure that the increased donation from Merck
is used effectively in endemic country settings in Africa
if the WHO NTDs Roadmap Targets of 2012, and
World Health Assembly Resolution WHA65.21, are to
be met. Maintaining or expanding efforts in the rest of
the world will need sustainable political and financial
commitment by countries where transmission has
reached the critical point towards elimination. Meeting
these targets will require building a robust coalition of
a multitude of stakeholders and securing stronger polit-
ical commitment in endemic countries especially, but
not exclusively, in Africa.
Building the Global Schistosomiasis Alliance
Such a coalition has now been established in the form of
the Global Schistosomiasis Alliance (GSA) in response
to the challenge afforded by WHA65.21 and in a manner
similar to other NTD coalitions [25].
The major aim of the GSA is to be a partnership of
endemic countries, academic and research institutions,
international development agencies and foundations,
international organizations, non-governmental develop-
ment organizations, private sector companies and advo-
cacy and resource mobilisation partners. Thereby, the
GSA can communicate with and between all different
stakeholders working on and engaged with schistosomia-
sis. While a number of key stakeholders have already be-
come member of the GSA, the GSA’s aim is to capitalise
upon the growing momentum for control and elimin-
ation of schistosomiasis and unite a growing number of
members who all work towards the objectives outlined
in WHA65.21. In particular, the GSA would welcome if
an increasing number of African based organisations
and institutions, as well as African governments were to
join the alliance.
The GSA is conceptualised as an independent organisa-
tion allowing for transparency, as well as allowing all
members to speak openly and independently. Further-
more, this organisational set-up respects the autonomy of
each partner and promotes efficient and effective govern-
ance. Thereby the GSA is hoping to create a space that
increases engagement and alignment among partners and
optimises the contribution of alliance members for the
greatest possible impact.
With elimination as the overarching objective, the
work of the GSA focuses on five interconnected themes,
presented below in Fig. 1.
The immediate focus lies on priority number one, im-
plementation. This refers to the provision of support to
the scale-up of preventive chemotherapy interventions
and other operational components for the control and
elimination of schistosomiasis based on successes already
achieved and lessons learned in several countries all over
the world. The communication of best practices between
countries and stakeholders and capacity building are con-
sidered central tasks of the GSA.
Secondly, research is an important part of the GSA’s
strategy towards elimination. Specific research areas to be
addressed, as well as research activities the GSA has en-
gaged in so far through its research working group are
outlined below in more detail. A third priority of the GSA
is advocacy work, both in endemic and non-endemic
countries, which will be coordinated with key regional
stakeholders. The aim is to raise awareness of the import-
ance to address schistosomiasis and to mobilise resources
together with GSA stakeholders. This links directly to the
fourth priority, which concerns communications. In order
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to deliver its key messages, the GSA employs a variety of
communication channels and tools, such as newsletters
and campaigns, to reach and target stakeholders. The
“Something in the Water” website (http://sitw.elimina-
teschisto.org/int/) is one such campaign, that reached
viewers globally and won six awards in 2016 for its cre-
ative approach. Finally, as the GSA becomes more estab-
lished, it will use its influence to continue to push its
mission to eliminate schistosomiasis as a public health
problem. The goal is to do so via a number of different ac-
tions, such as arriving at one common and shared defin-
ition of elimination and the required actions to achieve it,
coordinating and commissioning global research efforts,
as well as close collaboration with WHO to ensure opti-
mal allocation of resources that support schistosomiasis
elimination.
The latter will also be addressed by cooperation and col-
laboration with the STH Coalition, due to connections of
STH and schistosomiasis. The target set by WHO in the
NTD Road map for both STH and schistosomiasis is a
minimum 75% coverage with PC for all school age chil-
dren to be reached by 2020 [21, 22]. STH and schistosom-
iasis are also often found to be co-occurring in the same
communities [2] and shared treatment and medication
distribution as well as monitoring and evaluation are im-
portant aspects to be considered.
A number of working groups have been or will be set
up, covering the above mentioned strategically important
aspects. Details regarding these working groups can be
found in the table below Table 1.
The tasks of these working groups are to address the
areas where there is still much to learn, as for example
about the diagnostics needed in low transmission set-
tings and complementary interventions such as snail
control, behaviour change and water supply and sanita-
tion, through novel educational programmes targeting
mainly children. Moreover, the GSA and its members
are engaged in or support research into the development
of a paediatric formulation of PZQ [26], the relationship
between urogenital and female genital schistosomiasis
and HIV [27–29] and drug resistance [30, 31]. The im-
portance of collaborating with other NTDs is highlighted
by a recent article that discusses significant associations
between HIV infection, schistosomiasis and lymphatic
filariasis in terms of the host’s Th1- and Th2-type im-
mune responses [32].
The research and development working group is a
good example of activities so far, as it organised a con-
ference in Shanghai in June, 2016, in collaboration with
the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention, entitled
“Schistosomiasis Research: Providing the Tools Needed
for Elimination”, from which this Special Edition is
derived. Among the general but concrete outcomes of
necessary steps to take that all participants agreed on were
the need for the development of clearer alternative sched-
ules for the use of preventive chemotherapy and new
guidelines for the elimination of schistosomiasis with
Fig. 1 GSA Priority Areas
Table 1 Research Working Groups supporting GSA activities
1. Research and development
2. Implementation (enhance and support country programmes through,
e.g., project facilitation, technical support, capacity building and
training)
3. Monitoring and Evaluation
4. Promotion of quality control, supply and distribution of PZQ
5. Advocacy and resource mobilisation
6. Enhancement of collaboration and coordination with other NTD PC
programmes
7. Support of IEC (information, education & communication) activities
and community issues
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measurable recommendations for WASH as well as spe-
cific recommendations for snail control and the manage-
ment of persistent hot-spots.
The implementation working group is currently playing
an important role in the establishment and coordination
of a multi-stakeholder elimination project in Ethiopia. The
GSA has been bringing in different stakeholders, donors
and the Ministry of Health and coordinates amongst all
partners to develop and monitor an elimination approach.
The aim is to document the approach, with its strengths
and weaknesses in such a way that it can be used for and
applied to other settings. As part of the implementation
working group, effective monitoring and evaluation ap-
proaches have also already been targeted by the GSA. It is
currently working towards a revised set of programme
support milestones for the Uniting to Combat Scorecard
to allow for better tracking of the progress that is being
made and highlighting the areas that require more
attention.
In all its activities, the GSA is aware of the importance
not to duplicate any efforts or take over the responsibil-
ities of others. The GSA also considers it to be critical to
ensure that the schistosomiasis community recognises
the distinction between the programmatic responsibil-
ities of the WHO (which provide technical and stra-
tegic advice to endemic countries) and member states
of the WHO, that collaborate with non-governmental
development organizations (NGDOs), co-operate with
non-endemic member states through bilateral agree-
ments and are responsible for distribution of medicines
in the country. Furthermore, most donations, including
that of PZQ, are based upon a memorandum of under-
standing between the WHO and the specific pharma-
ceutical company. The GSA supports this set-up since
it facilitates coordination, forecasting and procurement
by member states of the WHO.
Conclusion
Ultimately the GSA is working for the benefit of en-
demic countries and providing support on the way to
schistosomiasis elimination. In turn, the growing econ-
omies of Africa will need to invest in schistosomiasis
elimination programmes in sustained ways. This will
demonstrate their commitment to reaching the sustain-
able development goals by 2030, to develop their rural
communities in an equitable way and to reduce the
burden of poverty in their countries. By uniting highly
committed stakeholders the GSA aims to support these
African countries by facilitating partnerships, which
address health inequities, reduce rural poverty, and
work towards the elimination of schistosomiasis for the
benefit of the world’s most vulnerable communities
with the ultimate objective to assure equitable human,
agricultural and economic development.
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